Biohaven’s Nurtec ODT (rimegepant) Receives the US FDA’s Approval for Treatment of Migraine

 Biohaven’s Nurtec ODT (rimegepant) Receives the US FDA’s Approval for Treatment of Migraine

Biohaven’s Nurtec ODT (rimegepant) Receives the US FDA’s Approval for Treatment of Migraine

Shots:

  • The approval is based on the P-III OLE trial involves assessing Nurtec ODT (rimegepant, 75 mg) vs PBO in patients with episodic migraine who experience less than 15 headache days/mos.
  • The 1EPs & 2EPs of the trial demonstrate a reduction in monthly migraine days by 4.3 days/mos. after 3mos. treatment, 50% patients reported at least >50% reduction in moderate-to-severe migraine days /mos., 95% of all US migraine patients experience less than 15 headache days/ mos.
  • Nurtec ODT (rimegepant) is the first and only CGRP receptor antagonist approved by the FDA for migraine as a dual therapy for both the acute and preventive treatment

Click here to­ read full press release/ article | Ref: PR Newswire | Image: PR Newswire

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post